GlassScriptPhysician profile
Ranilo L Vasquez
NPI 1669449211
$15,350.91
in general payments reported to CMS, 2019-2025
53 companies · $2,441 in 2025
The $2,441 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,547 · 2020: $1,614 · 2021: $2,673 · 2022: $2,533 · 2023: $2,201 · 2024: $2,342 · 2025: $2,441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,984.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,983.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,833.21 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $1,678.62 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $1,461.16 | 2021-2025 | Ubrelvy, Qulipta, Viberzi |
| Novo Nordisk INC | $962.93 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $852.59 | 2019-2025 | Jardiance |
| Pfizer INC. | $806.92 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $668.52 | 2022-2025 | |
| Lilly USA, LLC | $641.22 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $588.98 | 2019-2025 | Otezla, Repatha, Evenity |
| Kowa Pharmaceuticals America, INC. | $588.52 | 2019-2023 | Seglentis |
| Janssen Pharmaceuticals, INC | $529.99 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $498.41 | 2019-2022 | |
| Abbott Laboratories | $455.49 | 2019-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $449.39 | 2019-2023 | Veozah |
| Kvk-Tech, INC. | $365.40 | 2025 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ranilo Vasquez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.